Trial Profile
Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrhage as Complication of Exsudative Age-related Macular Degeneration (AMD).[ Intravitreale Lucentisinjektion (Ranibizumab) nach pars plana Vitrektomie und subretinaler Applikation von recombinant tissue plasminogen activator (rtPA) bei akuter submakulärer Blutung als Komplikation der exsudativen altersabhängigen Makuladegeneration (AMD).]
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 May 2019
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary) ; Alteplase
- Indications Ocular haemorrhage; Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms SubMacHem
- Sponsors Novartis
- 02 Mar 2016 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
- 12 Feb 2014 New source identified and integrated.German Clinical Trials Register (DRKS)
- 06 Jan 2014 New trial record